← FDA Drug Approvals (Drugs@FDA)

DAPAGLIFLOZIN

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: SCIEGEN PHARMACEUTICALS INC · Approved 2026-04-30

Drug application

FDA Application #

ANDA219408

Application type

Abbreviated New Drug Application (Generic)

Brand name

DAPAGLIFLOZIN

Generic name

Dapagliflozin

Active ingredients

DAPAGLIFLOZIN

Dosage form

TABLET

Route

—

Marketing status

None (Tentative Approval)

Sponsor

SCIEGEN PHARMACEUTICALS INC

First approval

2026-04-30

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown